Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Bo Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9944-0003; OpenAlex author ID A5100374384. Sources: OpenAlex.

Their work

Papers
2 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

  1. A practical distribution pattern of α-SMA-positive carcinoma associated fibroblasts indicates poor prognosis of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2025.102282↗
  2. β‑elemene inhibits the generation of peritoneum effusion in pancreatic cancer via suppression of the HIF1A‑VEGFA pathway based on network pharmacology. First author DOI 10.3892/or.2019.7360↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Suizhi Gao · 1 shared paper, 2025 · strength 0.20
  2. Kailian Zheng · 1 shared paper, 2025 · strength 0.20
  3. Xiongfei Xu · 1 shared paper, 2025 · strength 0.20
  4. Guoxiao Zhang · 1 shared paper, 2025 · strength 0.20
  5. Shiwei Guo · 1 shared paper, 2025 · strength 0.20
  6. Gang Jin · 1 shared paper, 2025 · strength 0.20
  7. Xiaoyi Yin · 1 shared paper, 2025 · strength 0.20
  8. Xiaohan Shi · 1 shared paper, 2025 · strength 0.20
  9. Meilong Shi · 1 shared paper, 2025 · strength 0.20
  10. Junqiu Zhu · 1 shared paper, 2019 · strength 0.11
  11. Hong Zhao · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.